PEN Stock Overview
Designs, develops, manufactures, and markets medical devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$270.27 |
| 52 Week High | US$310.00 |
| 52 Week Low | US$148.00 |
| Beta | 0.56 |
| 1 Month Change | -0.86% |
| 3 Month Change | 6.87% |
| 1 Year Change | 28.58% |
| 3 Year Change | 39.71% |
| 5 Year Change | 49.26% |
| Change since IPO | 554.41% |
Recent News & Updates
Recent updates
Penumbra Off And Running On Renewed Enthusiasm For Mechanical Thrombectomy
Mar 13Penumbra (NYSE:PEN) Will Be Hoping To Turn Its Returns On Capital Around
Jan 27
Penumbra: Re-Rated For The Wrong Reasons
Jan 07Investors Appear Satisfied With Penumbra, Inc.'s (NYSE:PEN) Prospects
Dec 31Penumbra (NYSE:PEN) May Have Issues Allocating Its Capital
Oct 06
CAVT Technology Powers Thrombectomy Leader To Transformative Growth And Global Expansion
Aug 27 Introduction of CAVT technology positions Penumbra as a thrombectomy leader, driving revenue growth through innovation and market share gains.Penumbra Grinding Through A Painful Growth Expectations Reset
Aug 20What You Can Learn From Penumbra, Inc.'s (NYSE:PEN) P/S
Aug 01Penumbra, Inc. (NYSE:PEN) Shares Could Be 23% Above Their Intrinsic Value Estimate
Jul 11Returns At Penumbra (NYSE:PEN) Appear To Be Weighed Down
Jun 19Penumbra: Appeal Improves As Operating Leverage Continues
May 30Penumbra: Appeal Improves, Just Not Appealing Yet
Oct 16Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy
Sep 01Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors
Jun 22Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M
Feb 23Penumbra Riding Higher On Upcoming Launches And Rerating
Jan 12Shareholder Returns
| PEN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.6% | 2.8% | 6.8% |
| 1Y | 28.6% | 2.9% | 5.9% |
Return vs Industry: PEN exceeded the US Medical Equipment industry which returned 1.7% over the past year.
Return vs Market: PEN exceeded the US Market which returned 4.8% over the past year.
Price Volatility
| PEN volatility | |
|---|---|
| PEN Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: PEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PEN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 4,500 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
Penumbra, Inc. Fundamentals Summary
| PEN fundamental statistics | |
|---|---|
| Market cap | US$10.49b |
| Earnings (TTM) | US$14.01m |
| Revenue (TTM) | US$1.19b |
742.9x
P/E Ratio8.7x
P/S RatioIs PEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEN income statement (TTM) | |
|---|---|
| Revenue | US$1.19b |
| Cost of Revenue | US$406.26m |
| Gross Profit | US$788.36m |
| Other Expenses | US$774.35m |
| Earnings | US$14.01m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 23, 2025
| Earnings per share (EPS) | 0.36 |
| Gross Margin | 65.99% |
| Net Profit Margin | 1.17% |
| Debt/Equity Ratio | 0% |
How did PEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 07:47 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Penumbra, Inc. is covered by 25 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| null null | Baird |
| Ishan Majumdar | Baptista Research |